Brief: MiNK Therapeutics Announces 77% Survival Rate In Intubated Patients With COVID-19 Respiratory Failure Treated With AgenT-797
12/11/2021 12:22
Nov 12 (Reuters) - Mink Therapeutics Inc INKT.O :
* MINK THERAPEUTICS ANNOUNCES 77% SURVIVAL RATE IN INTUBATED
PATIENTS WITH COVID-19 RESPIRATORY FAILURE TREATED WITH
AGENT-797
Source text for Eikon: ID:nGNX6pv84f
Further company coverage: INKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mink Therapeutics
See all newsMiNK Therapeutics Q2 loss narrows on expense discipline
Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's